|
|
10835 Road To The Cure, Suite 150
San Diego, CA 92121 USA
phone:858 812 7700
fax:858 812 7630
|
|
| Symbol |
Private |
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.braincellsinc.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Neurogenesis-based therapies for depression, mood disorders and other CNS diseases. |
|
| Management |
| James A. Schoeneck, Chief Executive Officer; Carrolee Barlow, M.D., Ph.D., Chief Scientific Officer; Steven D. Targum, M.D., Chief Medical Officer; Scott Wieland, Ph.D., Vice President, Clinical & Regulatory Affairs |
| |
|
|
| |
|
| Keywords |
| neurogenesis, depression, mood disorder, CNS disease, pre-clinical, drug discovery |
|
|
|
| Description |
|
BrainCells, Inc. is focused on the leading-edge neurogenesis-based drug discovery and development targeting novel therapies for depression, mood disorders and other CNS diseases. |
|
| Technology / Differentiation |
| BCI has licensed intellectual property, technology and know-how in neurogenesis, and is deploying its neurogenesis platform for profiling and selection of drug candidates. BCI believes that the platform represents a major improvement in the predictive power of pre-clinical models for CNS disorders, in particular depression and mood disorders, and will facilitate a paradigm-shift in CNS drug discovery. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members